GLP-1 and the cardiovascular system
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci194748 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Florian Kahles und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Cardiovascular Diseases, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular System. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The incretin hormone glucagon-like peptide-1 (GLP-1) exerts potent effects on glucose metabolism, prompting the development of therapeutic strategies that enhance activity of the GLP-1 receptor (GLP-1R) pathway. Inhibitors of dipeptidyl peptidase 4 (DPP-4) prolong the half-life of endogenous GLP-1 and typically achieve reductions in HbA1c of 0.5%–0.8%. However, large-scale cardiovascular (CV) outcomes trials (CVOTs) with DPP-4 inhibitors demonstrated CV safety but did not show a reduction in CV events. A second incretin-based therapeutic approach was the development of GLP-1R agonists (GLP-1RAs). Various GLP-1RAs, including liraglutide, semaglutide, and dulaglutide, demonstrated a reduction in CV outcomes in large CVOTs. Initially, these medications were only available as injectable agents for subcutaneous administration, but recent technological advancements have enabled the development of orally available GLP-1RAs. A third incretin-based approach is tirzepatide, a dual agonist of GLP-1R and glucose-dependent insulinotropic polypeptide receptor (GIPR), which achieves greater HbA1c reduction and weight loss compared with GLP-1RAs alone. Ongoing large-scale CVOTs will determine its effects on hard cardiovascular endpoints. This Review summarizes the effects of GLP-1 and GLP-1RAs in the CV system as well as clinical data of GLP-1RAs in individuals with CV disease or high CV risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen, Aachen, Germany.
- German Center for Diabetes Research (DZD), Neuherberg, Germany.
- Department of Internal Medicine IV, Diabetology, Endocrinology and Nephrology, Eberhard-Karls University Tübingen, Tübingen, Germany.
- Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich, Tübingen, Germany.
- School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences and Medicine, Kings College London, London, United Kingdom.
Zitieren
APA
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026). GLP-1 and the cardiovascular system. Journal of Clinical Investigation. https://doi.org/10.1172/jci194748
Vancouver
Kahles F, Birkenfeld AL, Marx N. GLP-1 and the cardiovascular system. Journal of Clinical Investigation. 2026. doi:10.1172/jci194748
BibTeX
@article{Kahles2026,
author = {Kahles, Florian and Birkenfeld, Andreas L and Marx, Nikolaus},
title = {GLP-1 and the cardiovascular system},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci194748}
}
EUVIMED